We are live on ! Find out more
PDSB icon

PDS Biotechnology

53 hedge funds and large institutions have $139M invested in PDS Biotechnology in 2016 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 26 increasing their positions, 7 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

271% more repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 7

161% more capital inflows, than outflows

Capital inflows: $26M | Capital outflows: $9.9M

140% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 5

15% more funds holding

Funds holding: 46 → 53 (+7)

6.16% more ownership

Funds ownership: 41.41% → 47.57% (+6.2%)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

Holders
53
Holders Change
+7
Holders Change %
+15.22%
% of All Funds
1.41%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
12
Increased
26
Reduced
7
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

PDSB Hedge Fund Activity: Q2 2016 in Review

53 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in PDS Biotechnology (PDSB) for Q2 2016, worth a combined $139M — up 27% from $109M a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new PDSB positions and 5 closed out — a net gain of 7 holders — while 26 added to existing stakes and 7 trimmed.

The largest buyer was Janus Henderson Investors US, adding an estimated $14.3M. The largest seller was Fidelity Investments, cutting an estimated $8.17M.

  • 53 institutional investors held PDS Biotechnology (PDSB) as of Q2 2016, up from 46 in Q1 2016.
  • Funds reported $139M of PDS Biotechnology stock for Q2 2016, up 27% quarter-over-quarter.
  • 12 funds opened new PDS Biotechnology positions in Q2 2016 and 5 closed out, a net change of +7 holders.
  • The largest PDS Biotechnology buyer in Q2 2016 was Janus Henderson Investors US, an estimated $14.3M added.
  • The largest PDS Biotechnology seller in Q2 2016 was Fidelity Investments, an estimated $8.17M sold.

Based on aggregated 13F filings for Q2 2016.